The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled studies …

SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting
millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins …

With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines,
functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS-…

In the absence of effective vaccines and with limited therapeutic options, convalescent plasma
is being collected across the globe for potential transfusion to coronavirus disease 2019 (…

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …

Perreault and colleagues examined antibody titers in sequential samples from serum
donors recovering from COVID-19 and demonstrated that antibody titers fall over 3-4 months. …

Intravenous immunoglobulin (IVIg) is currently evaluated in clinical trials for the treatment of
various disorders of the central nervous system. To assess its capacity to reach central …

Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-19,
is essential to help control the infection. The neutralization activity of plasma from patients …

Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19
pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in …

Human mesenchymal stromal cells (MSC) have been shown to dampen immune response
and promote tissue repair, but the underlying mechanisms are still under investigation. Herein…